Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.04 AUD | -13.04% | -16.67% | +81.82% |
May. 01 | Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6% | MT |
Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.36M 2.21M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.32M | Net income 2023 | -2M -1.32M | EV / Sales 2022 | - |
Net cash position 2022 | 1.1M 726K | Net cash position 2023 | 401K 264K | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.54
x | P/E ratio 2023 |
-1.35
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 63.89% |
1 day | -13.04% | ||
1 week | -16.67% | ||
Current month | -16.67% | ||
1 month | +17.65% | ||
3 months | +66.67% | ||
6 months | +42.86% | ||
Current year | +81.82% |
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 21-12-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 0.036 | -21.74% | 201,969 |
24-05-07 | 0.046 | -4.17% | 34,734 |
24-05-06 | 0.048 | 0.00% | 338,192 |
24-05-03 | 0.048 | 0.00% | 8,000 |
24-05-02 | 0.048 | -2.04% | 42,041 |
Delayed Quote Australian S.E., May 07, 2024 at 11:13 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+81.82% | 5.11M | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- ANR Stock